Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Systemic Treatment of Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given incombination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly con.
Systemic Treatment of Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regi...
Targeted Therapies in Oncology, Second Edition
Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.
Principles of Molecular Oncology
At the midpoint of the 20th century, our knowledge of cancer was based on epide- ology and pathology, and treatment consisted of surgery and radiation therapy. At mid-century, Medawar and colleagues initiated the understanding of transplantation immunology, Farber described the first use of an antifolic drug to treat leukemia, and Jacobson and coworkers described the irradiation-protection effect of spleen cells. These observations opened the door to the development of chemotherapy and tra- plantation in the treatment of cancer. Despite the rapid development of these new disciplines, progress was usually based on empiric observations and clinical trials. The rapid advances in molecular biology at the end of the 20th century mark a new era in our knowledge of cancer. Molecular immunology, molecular genetics, mole- lar pharmacology, and the Human Genome Project are in the process of providing a level of understanding of cancer undreamed of in the past. Optimism is based on the firm belief that understanding at the molecular level will lead to better and earlier di- nosis, to new forms of treatment, and, most importantly, eventually to prevention of many types of cancer.
Killer Algae
"This supposedly benign little plant - that no one thought could survive the waters of the Mediterranean - has become a pernicious force. Caulerpa taxifolia now covers 10,000 acres of the coasts of France, Spain, Italy, and Croatia, and has devastated Mediterranean ecosystems. And it continues to grow, unstoppable and toxic. When Alexandre Meinesz, a professor of biology at the University of Nice, learned of a square-yard patch of it in 1988, he warned biologists and oceanographers of the potential species invasion. His calls went unheeded. At that time, one person could have weeded the small patch and ended the problem. Since then, the plant has defeated the French Navy, thwarted scientific efforts to halt its rampage, and continues its destructive journey into the Adriatic Sea."--BOOK JACKET. "Killer Algae is the biological and political horror story of this invasion."--BOOK JACKET.
Nanoparticles in Cancer Therapy: Novel Concepts, Mechanisms and Applications
Since the invention of nanomedicine decades ago, considerable progresses have been made, especially with cancer as a target. Nanoparticles have been proven to be powerful imaging tools or potent agents for cancer diagnosis, treatment and prevention. Active research spread from fundamental research to clinical investigations. This topic intends to cover several important aspects in this field including nanocarrier development, gene delivery, intrinsically active nanoparticles, tumor microenvironment, immunology, and toxicity.
Textbook of Uncommon Cancer
Described as ‘must-have for cancer research’ by theHospital Doctor this highly acclaimed textbook has beenextensively revised and updated to reflect recent progress andunderstanding in the field. It is the only comprehensive source ofinformation available on uncommon cancers; presenting diagnosis,detailed clinical management and prognosis. The Textbook ofUncommon Cancer, Third Edition incorporated 18 newchapters, including: Tumors of the cervix Esthesioneuroblastoma Unusual malignancies of plasma cells Dermatofibrosarcoma protuberans Written by leading clinicians worldwide, this title isindispensable for all those involved in the diagnosis and treatmentof hard-to-manage rare tumors.
New Drugs for Malignancy, An Issue of Hematology/Oncology Clinics of North America
Topics include: Targeting IGF-1R, Tyrosine Kinase Inhibitors in Lung Cancer, Targeting mTOR, Targeting Hedgehog, Mitotic Inhibitors, Topoisomerase I Inhibitors , and New Strategies and Drugs Inhibiting Folate Pathways.
